Literature DB >> 3319407

Selection of appropriate antifungal therapy.

D M O'Day1.   

Abstract

Although there have been no radical breakthroughs in the treatment of fungal keratitis from the point of view of new antifungal agents, a better understanding of the epidemiology and pathology of the disease, as well as the drugs available and the appropriate surgical interventions, has led to an improvement in the management of this difficult corneal infection. In this paper the therapy of fungal keratitis will be reviewed in detail in the light of the known causative organisms and the pharmacology and pharmacokinetics of available antifungal agents.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3319407     DOI: 10.1097/00003226-198706040-00002

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  18 in total

1.  Measurements of antifungal levels in corneal tissue: a simplified bioassay for amphotericin B.

Authors:  T E Williams; D M O'Day; W S Head; R D Robinson
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

2.  Diagnosis of Fusarium keratitis in an animal model using the polymerase chain reaction.

Authors:  G Alexandrakis; S Jalali; P Gloor
Journal:  Br J Ophthalmol       Date:  1998-03       Impact factor: 4.638

3.  Orally administered antifungal therapy for experimental keratomycosis.

Authors:  D M O'Day
Journal:  Trans Am Ophthalmol Soc       Date:  1990

4.  Aetiology of suppurative corneal ulcers in Ghana and south India, and epidemiology of fungal keratitis.

Authors:  A K Leck; P A Thomas; M Hagan; J Kaliamurthy; E Ackuaku; M John; M J Newman; F S Codjoe; J A Opintan; C M Kalavathy; V Essuman; C A N Jesudasan; G J Johnson
Journal:  Br J Ophthalmol       Date:  2002-11       Impact factor: 4.638

5.  In vitro susceptibility of filamentous fungal isolates from a corneal ulcer clinical trial.

Authors:  Prajna Lalitha; Catherine Q Sun; N Venkatesh Prajna; Rajarathinam Karpagam; Manoharan Geetha; Kieran S O'Brien; Vicky Cevallos; Stephen D McLeod; Nisha R Acharya; Thomas M Lietman
Journal:  Am J Ophthalmol       Date:  2013-10-22       Impact factor: 5.258

6.  Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis.

Authors:  Daoud Al-Badriyeh; Chin Fen Neoh; Kay Stewart; David C M Kong
Journal:  Clin Ophthalmol       Date:  2010-05-06

7.  Genotypic identification of Fusarium species from ocular sources: comparison to morphologic classification and antifungal sensitivity testing (an AOS thesis).

Authors:  Eduardo C Alfonso
Journal:  Trans Am Ophthalmol Soc       Date:  2008

8.  A randomised clinical trial comparing 2% econazole and 5% natamycin for the treatment of fungal keratitis.

Authors:  N V Prajna; R K John; P K Nirmalan; P Lalitha; M Srinivasan
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

9.  Expert prior elicitation and Bayesian analysis of the Mycotic Ulcer Treatment Trial I.

Authors:  Catherine Q Sun; N Venkatesh Prajna; Tiruvengada Krishnan; Jeena Mascarenhas; Revathi Rajaraman; Muthiah Srinivasan; Anita Raghavan; Kieran S O'Brien; Kathryn J Ray; Stephen D McLeod; Travis C Porco; Nisha R Acharya; Thomas M Lietman
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-06-14       Impact factor: 4.799

10.  Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis.

Authors:  Catherine Q Sun; Prajna Lalitha; N Venkatesh Prajna; Rajarathinam Karpagam; Manoharan Geetha; Kieran S O'Brien; Catherine E Oldenburg; Kathryn J Ray; Stephen D McLeod; Nisha R Acharya; Thomas M Lietman
Journal:  Ophthalmology       Date:  2014-04-16       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.